Réthi-Nagy Zsuzsánna, Juhász Szilvia
Hungarian Centre of Excellence for Molecular Medicine, Cancer Microbiome Core Group, Budapesti út 9, Szeged H-6728, Hungary.
Hungarian Centre of Excellence for Molecular Medicine, Cancer Microbiome Core Group, Budapesti út 9, Szeged H-6728, Hungary.
J Biotechnol. 2024 Sep 10;392:161-179. doi: 10.1016/j.jbiotec.2024.07.002. Epub 2024 Jul 14.
The human microbiome is a diverse ecosystem of microorganisms that reside in the body and influence various aspects of health and well-being. Recent advances in sequencing technology have brought to light microbial communities in organs and tissues that were previously considered sterile. The gut microbiota plays an important role in host physiology, including metabolic functions and immune modulation. Disruptions in the balance of the microbiome, known as dysbiosis, have been linked to diseases such as cancer, inflammatory bowel disease and metabolic disorders. In addition, the administration of antibiotics can lead to dysbiosis by disrupting the structure and function of the gut microbial community. Targeting strategies are the key to rebalancing the microbiome and fighting disease, including cancer, through interventions such as probiotics, fecal microbiota transplantation (FMT), and bacteria-based therapies. Future research must focus on understanding the complex interactions between diet, the microbiome and cancer in order to optimize personalized interventions. Multidisciplinary collaborations are essential if we are going to translate microbiome research into clinical practice. This will revolutionize approaches to cancer prevention and treatment.
人类微生物组是一个多样化的微生物生态系统,它们存在于人体中并影响健康和幸福的各个方面。测序技术的最新进展揭示了以前被认为无菌的器官和组织中的微生物群落。肠道微生物群在宿主生理中发挥着重要作用,包括代谢功能和免疫调节。微生物组平衡的破坏,即生态失调,与癌症、炎症性肠病和代谢紊乱等疾病有关。此外,抗生素的使用会破坏肠道微生物群落的结构和功能,从而导致生态失调。靶向策略是通过益生菌、粪便微生物群移植(FMT)和基于细菌的疗法等干预措施来重新平衡微生物组和对抗包括癌症在内的疾病的关键。未来的研究必须专注于理解饮食、微生物组和癌症之间的复杂相互作用,以优化个性化干预措施。如果我们要将微生物组研究转化为临床实践,多学科合作至关重要。这将彻底改变癌症预防和治疗的方法。
J Biotechnol. 2024-9-10
Life Sci. 2021-8-1
Int J Mol Sci. 2024-9-8
Prog Mol Biol Transl Sci. 2022
Int Immunopharmacol. 2024-8-20
Int J Med Microbiol. 2018-5-9
World J Microbiol Biotechnol. 2025-7-28
Biomedicines. 2025-2-10